A Strategy and Action Plan for the Pharmaceutical Sector has
been adopted for the 2015-2018 period ("Action Plan"). It
was prepared by the General Directorate of the Ministry of Science,
Industry and Technology, with contributions from public and
non-governmental organizations, as well as universities. The Action
Plan is limited to pharmaceuticals for human use and sets goals for
the period to support the local pharmaceutical sector to become
more competitive globally.
The Action Plan envisages six strategic objectives and 36
specific actions, taking into account the key problems currently
facing the pharmaceutical sector. The strategic objectives are
Establish a qualified labour-force
which meets sector requirements.
Develop coordination and cooperation
by establishing a transparent environment, based on trust between
the public, universities, and private sector.
Ensure rational use of
pharmaceuticals by establishing informed doctors, dentists,
pharmacist, nurses and consumers population.
Plan R&D activities, ensure
coordination for the development of high quality products and
support products developed in this manner.
Establish a rational financial
structure which supports industry investments for the purpose of
supporting sustainability and globalization of the sector.
The Action Plan was announced in Official Gazette number 29440
on 9 August 2015. Please see this link for the full text (only available in
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Inquests are something which affect a vast range of NHS and private organisations, as well as individual clinicians, and so we provide a brief overview of recent developments as well as a couple of key potential changes to come.
Le 28 janvier dernier, le Président du Tribunal de grande instance de Nanterre, statuant en référé, a accordé des dommages et intérêts au titre du préjudice d'anxiété à certaines victimes du Mediator dans trois jugements.
The Turkish Competition Board has launched an investigation into the alleged blocking by the Turkish Pharmacists Union of "named patient sales" by pharmaceutical warehouses.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).